Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
VTP-300 as a monotherapy and in combination with a single administration of
low-dose nivolumab was administered, with no treatment-related serious adverse
events and infrequent transient transaminitis.
Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were
seen in some patients who received VTP-300 as either a monotherapy or in
combination with a single low dose of nivolumab at the booster dose. Declines
were most prominent in patients with lower baseline HBsAg.
All patients who received VTP-300 monotherapy or in combination with low-dose
nivolumab and who had a HBsAg decline greater than 0.5 log[10] had durable
reductions of HBsAg until the last measurement (up to eight months after last
dose).